Pharmamarketeer

Boehringer Ingelheim’s phase III INBUILD trial of nintedanib in patients across a range of progressive fibrosing interstitial lung diseases meets primary endpoint

Boehringer Ingelheim, a research─driven pharmaceutical company, announced that in the phase III INBUILD trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl